There is clinical and preclinical evidence supporting polydeoxyribonucleotide (PDRN, salmon DNA) for improving skin quality, particularly in the context of skin regeneration, anti-aging, and enhanced skin elasticity. However, while mechanistic and animal studies are robust, human clinical data are still limited and variable in quality. 

Multiple studies demonstrate that PDRN enhances collagen synthesis, reduces oxidative stress, and promotes extracellular matrix restoration, which are key factors in improving skin quality and counteracting age-related changes.PDRN acts via adenosine A2A receptor-mediated pathways, modulating macrophage and fibroblast interactions, and upregulating genes involved in tissue repair and anti-inflammatory responses.

Clinical and animal studies have shown improvements in skin elasticity, hydration, and reduction of pigmentation when PDRN is used alone or in combination with other agents (e.g., vitamin C, niacinamide).For example, topical and injectable PDRN formulations have been associated with increased collagen and elastin content, decreased melanin synthesis, and improved skin texture in both preclinical models and small human studies.

A recent review highlights that while polynucleotides are increasingly used in aesthetic medicine for skin rejuvenation, the degree of efficacy varies across studies, and further high-quality clinical trials are needed to establish optimal protocols and confirm long-term benefits.

In summary, PDRN (salmon DNA) shows promise for improving skin quality through multiple biological mechanisms, with supportive preclinical and early clinical data.